Aethlon Medical, Inc., announced today that the European Patent Office has granted European Patent Number 2591359, entitled “METHODS AND COMPOSITIONS FOR QUANTIFYING EXOSOMES.”
Embodiments of the present invention relate to methods, compositions and kits for quantifying exosomes. In particular, methods, composition and kits that utilize lectins to quantify exosomes are provided.
In recent years, exosomes have emerged as a significant diagnostic and therapeutic targets for a wide range of disease conditions, including cancer, infectious viruses, tuberculosis, Alzheimer’s, and chronic traumatic encephalopathy (CTE). This granted European Patent is an important addition to Aethlon Medical’s patent portfolio as it protects methods for quantifying any type of exosome captured by lectin affinity using Galanthus nivalis lectin (GNA), Narcissus pseudonarcissuslectin (NPA), Allium sativum lectin (ASA), Lens culinaris lectin (LCH), Sambucus nigra lectin (SNA), Maackia amurensis lectin (MAL) or concanavalin A. The patent has claims encompassing methods of quantifying exosomes associated with CTE, Alzheimer’s, cancer, or any other disease condition by contacting a sample having any type of exosome with GNA, NPA, ASA, LCH, SNA, MAL, or conconavalin A immobilized on a substrate, contacting the bound exosomes with a detectable exosome-binding agent, and measuring a signal from the bound detectable exosome-binding agent, thereby quantifying the bound exosomes. This European patent further expands Aethlon Medical’s established patent position on diagnostic and therapeutic approaches in the field of exosome biology.
Source – PR Newswire